STOCKWATCH: Missing the point
This article was originally published in Scrip
As investors in life science stocks, and biotechnology companies in particular, suffered another week of significant losses there are still voices of denial from the analyst community that have completely missed the point of what the market is telling them. The generalist investor is selling out of biotech and nothing can stop the exit.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.